STRO — Sutro Biopharma Share News
0.000.00%
Last trade - 00:00- $154.70m
- $229.42m
- $102.48m
Brief: Sutro Biopharma Q3 Revenue USD 9.693 Million
Brief: Sutro Biopharma says restructuring costs estimated at $4.1 million to $4.3 million - SEC filing
Brief: Sutro Biopharma announces operational restructuring intended to extend cash runway
Sutro Biopharma Inc reports results for the quarter ended June 30 - Earnings Summary
Sutro Biopharma Inc expected to post a loss of 38 cents a share - Earnings Preview
Sutro Biopharma Q2 revenue rises to $63.7 mln, net loss narrows
Sutro Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary
Sutro Biopharma Inc expected to post a loss of 49 cents a share - Earnings Preview
Brief: Sutro Biopharma Q1 Revenue USD 17.399 Million
U.S. RESEARCH ROUNDUP- Array Technologies, Nextracker, Sutro Biopharma
Brief: Sutro Biopharma Announces Strategic Portfolio Review Resulting In The Prioritization Of Its Next-Generation Adc Pipeline
Brief: Sutro Biopharma FY Revenue USD 62.043 Million
Sutro Biopharma Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Sutro Biopharma Q3 Revenue USD 8.52 Million
Sutro Biopharma Inc expected to post a loss of 73 cents a share - Earnings Preview
Brief: Sutro Biopharma Announces Initiation Of The Registration-Enabling REFRαME-P1 Trial With Luvelta For Pediatric Patients With CBF/GLIS AML
Brief: Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Sutro Biopharma Announces Updated Data From Phase 1B Study Of Luvelta In Combination With Bevacizumab At Esmo 2024
Brief: Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer